TABLE 2.
Anticancer treatments by line of therapy.
| LoT 1, N (%) | LoT 2, N (%) | LoT 3, N (%) | LoT 4, N (%) | LoT 5, N (%) | |
|---|---|---|---|---|---|
| Number of patients receiving each LoT | |||||
| Overall | 105 | 99 | 69 | 41 | 17 |
| Asian | 41 | 39 | 25 | 13 | 7 |
| Non‐Asian | 64 | 60 | 44 | 28 | 10 |
| Chemotherapy, N (%) | |||||
| Overall a | 76 (72.4%) | 30 (30.3%) | 24 (34.8%) | 17 (41.5%) | 7 (41.2%) |
| Asian b | 26 (63.4%) | 14 (35.9%) | 8 (32.0%) | 7 (53.8%) | 1 (14.3%) |
| Non‐Asian c | 50 (78.1%) | 16 (26.7%) | 16 (36.4%) | 10 (35.7%) | 6 (60.0%) |
| EGFR TKI, N (%) | |||||
| Overall a | 16 (15.2%) | 56 (56.6%) | 28 (40.6%) | 14 (34.1%) | 5 (29.4%) |
| Asian b | 11 (26.8%) | 20 (51.3%) | 11 (44.0%) | 4 (30.8%) | 3 (42.9%) |
| Non‐Asian c | 5 (7.8%) | 36 (60.0%) | 17 (38.6%) | 10 (35.7%) | 2 (20.0%) |
| Mobocertinib, N (%) | |||||
| Overall a | 9 (8.6%) | 53 (53.5%) | 26 (37.7%) | 12 (29.3%) | 4 (23.5%) |
| Asian b | 4 (9.8%) | 20 (51.3%) | 10 (40.0%) | 4 (30.8%) | 2 (28.6%) |
| Non‐Asian c | 5 (7.8%) | 33 (55.0%) | 16 (36.4%) | 8 (28.6%) | 2 (20.0%) |
| Amivantamab, N (%) | |||||
| Overall a | 1 (1.0%) | 3 (3.0%) | 12 (17.4%) | 6 (14.6%) | 5 (29.4%) |
| Asian b | 1 (2.4%) | 2 (5.1%) | 4 (16.0%) | 0 | 3 (42.9%) |
| Non‐Asian c | 0 | 1 (1.7%) | 8 (18.2%) | 6 (21.4%) | 2 (20.0%) |
| IO Agents, N (%) | |||||
| Overall a | 27 (25.7%) | 12 (12.1%) | 5 (7.2%) | 2 (4.9%) | 0 |
| Asian b | 8 (19.5%) | 4 (10.3%) | 1 (4.0%) | 2 (15.4%) | 0 |
| Non‐Asian c | 19 (29.7%) | 8 (13.3%) | 4 (9.1%) | 0 | 0 |
| Monoclonal antibodies, N (%) | |||||
| Overall a | 8 (7.6%) | 9 (9.1%) | 19 (27.5%) | 10 (24.4%) | 6 (35.3%) |
| Asian b | 3 (7.3%) | 4 (10.3%) | 4 (16.0%) | 1 (7.7%) | 3 (42.9%) |
| Non‐Asian c | 5 (7.8%) | 5 (8.3%) | 15 (34.1%) | 9 (32.1%) | 3 (30.0%) |
Note: Treatments are not mutually exclusive. The Definition of treatment categories is included in Methods section.
Abbreviations: EGFR TKI = epidermal growth factor receptor tyrosine kinase inhibitor; IO = Immuno‐oncologic; LoT = line of therapy; N = number.
Denominator is the number of patients at each LoT (provided in the “N total” row)—for example, 76 of 105 patients (72.4%) received chemotherapy at LoT 1.
Denominator for the Asian treatment row is the number of Asian patients within the LoT (provided in the “N total” row)—for example, 26 of 41 Asian patients (63.4%) at LoT 1 received chemotherapy.
Denominator for the non‐Asian treatment row is the number of non‐Asian patients within the LoT (provided in the “N total” row); for example, 50 of 64 non‐Asian patients (78.1%) at LoT 1 received chemotherapy.